ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
G3BP1 Succinylation at K413 is Critical for Cardiac Function by Modulating PI3K-AKT-mTOR Signal Axis.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
G3BP1, GTPase activating protein (SH3 domain) binding protein 1, is a core component of stress granules. Homozygous null mutations in the G3bp1 gene result in embryonic lethality, underscoring its essential role in development. While various post-translational modifications regulate G3BP1 activity, here we first report that G3BP1 undergoes succinylation (Suc) at Lys (K)411 in mouse hearts (corresponding to human K413). G3BP1-Suc level was diminished in Myosin binding protein C3 (Mybpc3) knockout and transverse aortic constriction (TAC) operated mice, which developed heart failure (HF). Site-directed mutagenesis confirmed that the K413R mutation compromised the overall Suc level of G3BP1 in vitro. Mice injected with AAV9-G3BP1 (WT) developed typical phenotypes of dilated cardiomyopathy (DCM) and HF when compared to mice injected with AAV9-Ctrl and -G3BP1 (K411R) mice, suggesting a possible loss of functional effect of de-Suc at K411. Moreover, Homozygous knock-in G3bp1 (K411R) mice exhibited compromised cardiac parameters compared to WT littermates. De novo G3BP1 mutation (p.E411G) from a DCM patient disrupts Suc at K413. Mechanistically, G3BP1 de-Suc at K413 induced Rraga expression and impaired TSC1/2 and IDE binding, ultimately leading to excessive activation of the PI3K-AKT-mTOR signaling axis. We demonstrate a critical role for G3BP1 Suc at K413 in cardiac function by modulating the PI3K-AKT-mTOR pathway, providing new insights into the non-canonical function of G3BP1 in cardiomyopathy and HF pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.